I
Infiltrate Bio provides an adhesion biomarker platform that predicts the ability of immune cells to infiltrate solid tumors. The technology uses quantitative adhesion chromatography to screen and optimize cell therapy candidates, improving development efficiency and manufacturing consistency. Researchers can access the platform and expert consultation through innovation grants to accelerate preclinical and clinical programs.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This company provides an adhesion biomarker platform utilizing advanced adhesion chromatography to model tumor vasculature. The platform identifies therapeutic candidates with high infiltration potential for solid tumor cell therapies. This capability accelerates cell therapy development by predicting immune cell navigation to cancer sites.